BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first
quarter 2019 financial results on Thursday, May 9, 2019, prior to the
open of the U.S. financial markets. The Company will host a conference
call and live webcast with the investment community at 8:30 a.m.,
Eastern Time on May 9, 2019.
The financial results and live webcast will be accessible through the
Investor Relations section of the Company's Web site at https://investors.amneal.com.
The webcast can also be accessed at the following URL: https://event.on24.com/wcc/r/1956483/BE86212DB4A693962AB0C83F08260E1C
To access the call through a conference line, dial (866) 652-5200 (in
the U.S.) and (412) 317-6060 (international callers).
A replay of the conference call will be available for seven days shortly
after the call. To access the replay, dial (877) 344-7529 (in the U.S.)
and (412) 317-0088 (international callers). The access code for the
replay is 10130469.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in
Bridgewater, NJ, is an integrated pharmaceutical company focused on
developing, manufacturing and distributing generic, brand and biosimilar
products. The Company has approximately 6,000 employees in its
operations in North America, Asia, and Europe, working together to bring
high-quality medicines to patients primarily within the United States.
Amneal is one of the largest generic pharmaceutical manufacturers in the
United States, with an expanding portfolio of generic products to
include complex dosage forms in a broad range of therapeutic areas. The
Company also markets a portfolio of branded pharmaceutical products
through its Specialty Pharma division focused principally on central
nervous system disorders, endocrinology and parasitic infections. For
more information, visit www.amneal.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190408005421/en/
Mark Donohue
Investor Relations and Corporate Communications
(908)
409-6718
www.amneal.com
Source: Amneal Pharmaceuticals, Inc.